In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary
discussions of surgical resectability and medical operability determine the modality of …

Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-
small cell lung cancer (NSCLC), but its efficacy and impact on the immune …

Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally
advanced stage disease. We aimed to assess the antitumour activity and safety of …

Background Previous phase 2 trials of neoadjuvant anti-PD-1 or anti-PD-L1 monotherapy in
patients with early-stage non-small-cell lung cancer have reported major pathological …

Background Approximately 25% of all patients with non-small-cell lung cancer present with
resectable stage IB–IIIA disease, and although perioperative chemotherapy is the standard …

PURPOSE For patients with resectable stage IIIA (N2) non–small-cell lung cancer,
neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1 …

Introduction Programmed death receptor-1 (PD-1) inhibitors have shown efficacy in first-line
treatment of NSCLC; however, evidence of PD-1 inhibitor as neoadjuvant treatment is …

Currently, there is no established guidance on how to process and evaluate resected lung
cancer specimens after neoadjuvant therapy in the setting of clinical trials and clinical …

Cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4) or programmed death-1 (PD-
1)/programmed death-ligand 1 (PD-L1)–based immune checkpoint inhibitors (ICIs) have led …